Local organizations, researchers continue to win CPRIT funding In addition to hosting clinical trials, MD Anderson also continued to secure CPRIT funding. The cancer research center was awarded ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Called cryoablation, the procedure has not been federally approved for breast cancer treatment, but clinical trials are ...

Under the agreements, AmMax and MD Anderson will build upon preclinical discoveries made by MD Anderson researchers to evaluate the potential for AMB-066, which targets colony stimulating factor 1 ...

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer ...

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH)—a rare, aggressive ...

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical trial ...

BIRMINGHAM, AL, USA I 4, 2024 I Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in ...

A new study from researchers at The University of Texas MD Anderson Cancer ... for developing cancer." This research was supported by the National Cancer Institute (RO1CA240526, RO1CA236864, ...